Literature DB >> 17088645

Cernunnos-XLF, a recently identified non-homologous end-joining factor required for the development of the immune system.

Patrick Revy1, Laurent Malivert, Jean-Pierre de Villartay.   

Abstract

PURPOSE OF REVIEW: The analysis of immune deficiency conditions in humans has recently allowed the identification of a novel factor, Cernunnos, involved in DNA repair and required during the development of the immune system. The present review will focus on the information and new questions provided by the discovery of Cernunnos. RECENT
FINDINGS: The study of human immune deficiency conditions associated with defective DNA repair led to the recent identification of Cernunnos. Cernunnos is required for the ubiquitous DNA repair process mainly used in mammals, the non-homologous end-joining pathway. The analysis of Cernunnos defect conditions demonstrated the essential role of this novel factor during the development of the immune system. Cernunnos is homologous to the non-homologous end-joining factor, XRCC4, and is the genuine homologue of the yeast non-homologous end-joining factor, Nej1. These observations shed new light on the process underlying the last step of the non-homologous end-joining pathway, the DNA ends ligation.
SUMMARY: The elucidation of the molecular bases of rare inherited immune deficiencies associated with DNA repair defects provide considerable insights into our understanding of fundamental mechanisms such as the non-homologous end-joining ubiquitous DNA repair pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17088645     DOI: 10.1097/01.all.0000246623.72365.43

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  11 in total

Review 1.  Quality control of DNA break metabolism: in the 'end', it's a good thing.

Authors:  Roland Kanaar; Claire Wyman; Rodney Rothstein
Journal:  EMBO J       Date:  2008-02-20       Impact factor: 11.598

2.  DNA Ligase IV regulates XRCC4 nuclear localization.

Authors:  Dailia B Francis; Mikhail Kozlov; Jose Chavez; Jennifer Chu; Shruti Malu; Mary Hanna; Patricia Cortes
Journal:  DNA Repair (Amst)       Date:  2014-06-28

Review 3.  Recent advances in the study of immunodeficiency and DNA damage response.

Authors:  Tomohiro Morio
Journal:  Int J Hematol       Date:  2017-05-26       Impact factor: 2.490

4.  XRCC4/XLF Interaction Is Variably Required for DNA Repair and Is Not Required for Ligase IV Stimulation.

Authors:  Sunetra Roy; Abinadabe J de Melo; Yao Xu; Satish K Tadi; Aurélie Négrel; Eric Hendrickson; Mauro Modesti; Katheryn Meek
Journal:  Mol Cell Biol       Date:  2015-06-22       Impact factor: 4.272

Review 5.  Functional overlaps between XLF and the ATM-dependent DNA double strand break response.

Authors:  Vipul Kumar; Frederick W Alt; Valentyn Oksenych
Journal:  DNA Repair (Amst)       Date:  2014-02-20

6.  Defects in XRCC4 and KU80 differentially affect the joining of distal nonhomologous ends.

Authors:  Josée Guirouilh-Barbat; Emilie Rass; Isabelle Plo; Pascale Bertrand; Bernard S Lopez
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-18       Impact factor: 11.205

7.  Recruitment and dissociation of nonhomologous end joining proteins at a DNA double-strand break in Saccharomyces cerevisiae.

Authors:  Dongliang Wu; Leana M Topper; Thomas E Wilson
Journal:  Genetics       Date:  2008-02-03       Impact factor: 4.562

Review 8.  Is non-homologous end-joining really an inherently error-prone process?

Authors:  Mireille Bétermier; Pascale Bertrand; Bernard S Lopez
Journal:  PLoS Genet       Date:  2014-01-16       Impact factor: 5.917

9.  Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer.

Authors:  Zhuo Liu; Miao Yu; Bingyuan Fei; Jing Sun; Dongxin Wang
Journal:  Onco Targets Ther       Date:  2019-03-20       Impact factor: 4.147

10.  Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.

Authors:  Thuy-Vy Do; Jeff Hirst; Stephen Hyter; Katherine F Roby; Andrew K Godwin
Journal:  Oncotarget       Date:  2017-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.